|
WO2021081101A1
|
|
Anti-beta-amyloid antibody for treating alzheimer's disease
|
|
WO2021034924A1
|
|
Trans-cyclooctene labeled antisense oligonucleotides, radio labeled tetrazine and methods
|
|
WO2021030766A1
|
|
Combination therapy for spinal muscular atrophy
|
|
WO2021026461A2
|
|
Potency assays for viral vector production
|
|
WO2021016032A1
|
|
Methods of treating or preventing spinal muscular atrophy
|
|
UY38766A
|
|
DERIVATIVES OF IMIDAZO [1,2-A] PYRIDINYL AND THEIR USE IN THE TREATMENT OF DISEASES
|
|
UY38765A
|
|
DERIVATIVES OF 2H-INDAZOLE AND THEIR USE IN THE TREATMENT OF DISEASES
|
|
WO2020232330A1
|
|
Inhibiting agents for bruton's tyrosine kinase
|
|
WO2020227618A2
|
|
Convergent liquid phase syntheses of oligonucleotides
|
|
WO2020219897A1
|
|
Methods for production of recombinant adeno-associated viruses
|
|
WO2020210485A1
|
|
Process for preparing alpha-carboxamide pyrrolidine derivatives
|
|
WO2020210358A1
|
|
Anti-integrin antibodies and uses thereof
|
|
WO2020185750A1
|
|
Pharmaceutical compositions containing anti-lingo-1 antibodies
|
|
WO2020185593A1
|
|
Azetidinyl 0-glyc0pr0tein-2-acetamid0-2-deoxy-3-d-gluc0pyran0sidase inhibitors
|
|
WO2020167715A1
|
|
Biomarkers of progressive multifocal leukoencephalopathy
|
|
WO2020163193A1
|
|
Bicyclic ether o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
|
|
WO2020154607A1
|
|
Seed culture process for aav production
|
|
WO2020150626A1
|
|
Imidazo[1,2-a]pyridinyl derivatives as irak4 inhibitors
|
|
TW202035694A
|
|
Compositions and methods for treating and preventing amyotrophic lateral sclerosis
|
|
TW202039482A
|
|
Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
|
